Skip to content
lifestyle.tvshowauditions.info
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Immix Biopharma, Inc.
Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
November 4, 2026
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
October 5, 2026
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
September 29, 2026
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
September 29, 2026
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
May 22, 2026
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
May 21, 2026
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
May 21, 2026